However, no results have been published yet and the molecular mechanism(s) responsible for pentamidine anticancer activity remains largely unclear, except for the observation that pentamidine can inhibit oncogenic PRL phosphatases.39 This study demonstrates that through the direct inhibition of wtp53 function, S100B may contribute to cancer cells' genomic instability, thus increasing the chance to escape to standard anticancer therapies. Here, S100B is linked to cancer.